Charted
Wednesday, Nov. 18, 2026The business of health, by the numbers
Live trackersDeal tracker $7.07B raisedFDA clearances 293 510(k)s in OctoberForm D raises $839M in 30 daysNew trials 266 Phase 2/3 in 30 days
Health Tech·Doximity

Doximity's costs outpace 4% revenue growth, and adjusted EBITDA falls 12% to $88.9M

Revenue rose 4% to $174.5 million and beat Doximity's own forecast, but cost of revenue and operating expenses grew much faster, and net income fell to $34.7 million from $62.1 million.

From Doximity's fiscal second-quarter earnings release, filed with the SEC Nov. 5, 2026, and its fiscal first-quarter release for prior guidance
A Navy physician at Naval Hospital Jacksonville's family medicine clinic holds a virtual visit by laptop.
A Navy physician at Naval Hospital Jacksonville's family medicine clinic holds a virtual visit by laptop. File photo.U.S. Navy (public domain)

Doximity sold more in its fiscal second quarter than it had told investors to expect. It also spent much more.

The physician network said Nov. 5 that revenue for the quarter ended Sept. 30 rose 4% to $174.5 million from $168.5 million, above the $170 million to $171 million it had forecast in August. Adjusted EBITDA, as the company defines it, fell 12% to $88.9 million from $100.8 million, though that also beat its forecast of $80.5 million to $81.5 million.

Why it matters: Doximity's adjusted EBITDA margin narrowed to 50.9% from 59.8% in a year as its costs grew far faster than its sales. Cost of revenue rose about 54% to $25.3 million and operating expenses about 19% to $105.3 million, while revenue grew by about $6 million.

Jeff Tangney, co-founder and chief executive, said in the release that the company kept a 51% adjusted EBITDA margin "while investing heavily in AI." He said more than 190 health systems have bought its AI suite. The release did not say how much of the cost increase came from that investment.

Where the money went

Research and development expense rose to $42.0 million from $30.2 million, and sales and marketing to $46.9 million from $39.2 million. General and administrative expense fell to $16.4 million from $19.0 million. Stock-based compensation, which is spread across cost of revenue and those expense lines, totaled $40.6 million, up from $29.5 million.

Net income fell to $34.7 million, or 18 cents a diluted share, from $62.1 million, or 31 cents, and net margin dropped to 19.9% from 36.8%. Non-GAAP net income was $68.3 million, or 36 cents a share, compared with $90.0 million, or 45 cents.

Cash generation held steady. Operating cash flow was $93.3 million, down 1%, and free cash flow was $91.3 million, compared with $91.6 million a year earlier. Doximity ended September with $218.6 million in cash and cash equivalents and $494.6 million in marketable securities.

The company

Doximity, founded in 2010, describes itself as a digital platform for U.S. medical professionals. It says more than 85% of U.S. physicians are members of its network and that it offers clinical reference and search tools built on AI. It describes its mission as making doctors more productive.

What to watch

For the fiscal third quarter ending Dec. 31, Doximity forecast revenue of $195 million to $196 million and adjusted EBITDA of $102.5 million to $103.5 million. At the midpoints, that would be an adjusted EBITDA margin of about 53%.

For the full fiscal year ending March 31, 2027, it now expects revenue of $678 million to $683 million, up from $671 million to $681 million in August. It narrowed its adjusted EBITDA forecast to $317 million to $325 million from $309 million to $329 million, lifting the midpoint by $2 million. Whether costs keep rising faster than revenue will show up first in that third-quarter margin.

Sara Montes de Oca is the Editor in Chief of Charted. She previously worked as a correspondent and producer in Washington, D.C., covering business, finance, and politics. Drafted with automated tools from the sources listed with this story and checked against them before publishing. How we report.

More Health Tech

More
Newsletter

Charted Daily

The day's deals, FDA decisions and policy moves, by the numbers. Free. Sign up now to get the first edition.

No spam. Unsubscribe any time.